Get the Stockscreener App
1,031.96
3.89%
-41.33
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,031.96, with a volume of 2.73M.
It is down -3.89% in the last 24 hours and down -2.89% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,073.29
Open:
$1062.56
24h Volume:
2.73M
Relative Volume:
0.80
Market Cap:
$923.59B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
51.04
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-4.95%
1M Performance:
-2.89%
6M Performance:
+33.66%
1Y Performance:
+38.14%
1-Day Range:
$1,012.57
$1,067.65
1-Week Range:
$1,012.57
$1,104.52
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,031.92 | 960.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
219.00 | 526.55B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
217.19 | 392.16B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.68 | 275.53B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
142.54 | 280.45B | 54.45B | 14.42B | 17.15B | 7.333 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Where is Eli Lilly and Company (LLY) Headed According to Analysts? - Finviz
Nvidia and Lilly to create AI co-innovation lab - The Pharma Letter
Eli Lilly (LLY) Stock Dips Amid FDA Review Delay on Weight-Loss Pill - GuruFocus
AMD, Eli Lilly among market cap stock movers on Thursday - Investing.com
Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy - Reuters
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent - PharmaLive
JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus - Clinical Trials Arena
Eli Lilly and Company Stock (LLY) Opinions on Obesity Drug Partnership and AI Investment - Quiver Quantitative
JPM26: Eli Lilly’s obesity drugs target commercial and governmental access - Pharmaceutical Technology
WealthPLAN Partners LLC Grows Position in Eli Lilly and Company $LLY - MarketBeat
WealthPlan Investment Management LLC Has $1.56 Million Stake in Eli Lilly and Company $LLY - MarketBeat
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks - Benzinga
Eli Lilly slips in pre-market! New pill still under FDA scrutiny 💊 - XTB.com
Eli Lilly shares dip as FDA delays decision on weight-loss pill - Investing.com
2,142 Shares in Eli Lilly and Company $LLY Bought by Touchstone Capital Inc. - MarketBeat
The Truth About Eli Lilly: Is Wall Street’s Favorite Pharma Stock Still Worth the Hype? - AD HOC NEWS
Retirement Planning Group LLC Has $1.14 Million Stake in Eli Lilly and Company $LLY - MarketBeat
NVIDIA and Eli Lilly Target AI Medicine Manufacturing - Healthcare Digital
Arcadia Investment Management Corp MI Purchases 1,995 Shares of Eli Lilly and Company $LLY - MarketBeat
Ashton Thomas Securities LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Compounding Pharmacy Accuses Eli Lilly, Novo Nordisk of Blocking GLP-1 Competition - USA Herald
Eli Lilly’s Strategic Moves: FDA Timeline, AI Partnership, and Legal Hurdles - AD HOC NEWS
Eli Lilly, Novo Hit With Antitrust Suit From Drug Compounder (1) - Bloomberg Law News
Eli Lilly (LLY) and Novo Nordisk Face Legal Battle Over GLP-1 Dr - GuruFocus
Compounding pharmacy sues Lilly, Novo over GLP-1 drug competition - Seeking Alpha
Eli Lilly’s Next Strategic Move: An Oral Contender for the Weight-Loss Market - AD HOC NEWS
Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk - PR Newswire
Behind the Scenes of Eli Lilly and Co's Latest Options TrendsEli Lilly and Co (NYSE:LLY) - Benzinga
NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery - Oncodaily
How Eli Lilly’s US$1 Billion NVIDIA AI Lab Could Reshape Growth, Margins and Pipeline (LLY) - simplywall.st
LLY Shows Positive Momentum Amid Obesity Drug Industry Developme - GuruFocus
Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground - Benzinga
NVIDIA and Eli Lilly Launch $1bn AI Drug Discovery Lab - AI Magazine
Lilly and NVIDIA unveil $1B co-innovation lab in South San Francisco - drugdiscoverytrends.com
JP Morgan 2026: Eli Lilly’s Continuing GLP-1 Success - PharmExec.com
BMO Capital Markets Pounds the Table on Eli Lilly Stock (LLY) - TipRanks
Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery - Longevity.Technology
Nvidia, Eli Lilly to Invest USD 1 Billion in AI Co-Innovation Lab for Drug Discovery - TelecomTalk
BMO Capital reiterates Outperform rating on Eli Lilly stock at $1,200 - Investing.com
Is It Time to Dump Your Shares of Eli Lilly? - Finviz
Eli Lilly and Company $LLY is Wealth Advisory Solutions LLC's 4th Largest Position - MarketBeat
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly - Investing.com
Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug - Bloomberg.com
Jim Cramer Calls Nvidia, Eli Lilly Partnership 'Monumental Effort' To 'Speed Up' Critical Drug Creation - Benzinga
NVIDIA, Lilly Launch AI Lab to Transform Drug Discovery Innovations - filmogaz.com
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - MarketBeat
French Government Shoots Down Rumors Eli Lilly (LLY) Is Planning to Acquire Biotech Firm Abivax - TipRanks
Eli Lilly CFO: Weight-loss pill could have 20% global penetration - Yahoo Finance UK
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
Patients file lawsuits in Marion Co. alleging drug companies "downplayed" GLP-1 side effects - WRTV
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms - TechStock²
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):